Searching for smart, safe news you can TRUST?
Support safe, smart, REAL journalism. Sign up for our Axios AM & PM newsletters and get smarter, faster.
Searching for smart, safe news you can TRUST?
Support safe, smart, REAL journalism. Sign up for our Axios AM & PM newsletters and get smarter, faster.
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Minneapolis-St. Paul
Tampa-St. Petersburg news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa-St. Petersburg
Photo: Paul J. Richards/AFP/Getty Images
The Federal Trade Commission plans to hold antitrust hearings later this year, and health care groups haven't been shy about telling regulators this month what they want done with the pharmaceutical industry.
Between the lines: The Hatfields and the McCoys still have guns pointed toward each other.
What they're saying:
- Consumer groups teamed up with America's Health Insurance Plans to urge the FTC to "stop sham and anticompetitive transactions that unnecessarily delay generic drug and biosimilar competition."
- Former Rep. Henry Waxman told the FTC it should conduct a deep analysis of pharmacy benefit manager consolidation and how PBM contracts affect drug prices.
- PhRMA, building on its long campaign against PBMs, similarly wants pharmacy benefit rebates to be scrutinized.